Back to search
FDAFDA · Food and drugs·Recall number Z-0479-2014

Aesculap GNI161 Bipolar Foot Control Product Usage: The Aesculap Bipolar Coagulator is intended for use in surgery to generate electrical power for bipolar instruments. Bipolar coagulators are used in neurosurgery, ENT surgery, urology, laparoscopy, and plastic surgery.

Published December 18, 2013 · Recall initiated: September 10, 2013

Summary

FDA records medical device Class II recall Z-0479-2014, published December 18, 2013 and initiated September 10, 2013. Recalling firm: Aesculap, Inc.; Status: Terminated; Reported quantity: 85; Lot: all GN161's distributed between 4/28/2009 and 5/22/2013. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Complaints were received for the GN161 Bipolar Foot Control reporting that the bipolar energy did not stop after release of the foot control.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Aesculap, Inc.
Distributor
Worldwide Distribution - USA Nationwide and countries of: Austria, Germany, Japan, and Taiwan.
Lot
all GN161's distributed between 4/28/2009 and 5/22/2013.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Aesculap GNI161 Bipolar Foot Control Product Usage: The Aesculap Bipolar Coagulator is intended for use in surgery to generate electrical power for bipolar instruments. Bipolar coagulators are used in neurosurgery, ENT surgery, urology, laparoscopy, and plastic surgery. recalled?

Yes. FDA published recall Z-0479-2014 on December 18, 2013. Reported hazard: Complaints were received for the GN161 Bipolar Foot Control reporting that the bipolar energy did not stop after release of the foot control.

What should I do if I have this product?

Voluntary: Firm initiated · Letter